Abeona Therapeutics Scales Up Production Of rAAV Using AAV293 Suspension Cells In The Allegro™ STR Bioreactor System

Reliable and scalable viral vector manufacturing platforms are needed to accommodate the increased demand as more gene therapy treatments are brought to market. These transformative medicines can be used to replace a defective gene with a functional copy, silence a defective gene or even be introduced to directly edit genes in vivo. Not only is the diversity of target indications growing, but the size of the patient population is as well, necessitating better upstream technologies to meet the increased viral vector demand that drive these therapies.

Improving manufacturing scalability and productivity of viral vectors is a goal for many companies invested in gene therapies. Abeona Therapeutics is a gene therapy company developing novel gene replacement therapies for rare inherited diseases. In an effort to optimize production processes for their rAAV-based gene therapy product, Abeona Therapeutics evaluated the Pall Allegro™ STR single use family of bioreactors as a potential solution to the scalability problem.

Read how their ability to leverage scalable production platforms such as the Allegro STR suite of bioreactors made process development and subsequent scale-up more streamlined offering time and cost savings that ultimately benefits high-need patients.